[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 139,097,824
  • Shares Outstanding, K 253,805
  • Annual Sales, $ 12,001 M
  • Annual Income, $ 3,953 M
  • EBIT $ 4,777 M
  • EBITDA $ 4,987 M
  • 60-Month Beta 0.30
  • Price/Sales 11.43
  • Price/Cash Flow 31.41
  • Price/Book 6.92

Options Overview Details

View History
  • Implied Volatility 30.07% (-0.10%)
  • Historical Volatility 29.27%
  • IV Percentile 47%
  • IV Rank 33.09%
  • IV High 46.24% on 02/12/26
  • IV Low 22.08% on 08/27/25
  • Expected Move (DTE 6) 17.79 (3.25%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 1,902
  • Volume Avg (30-Day) 2,816
  • Put/Call OI Ratio 1.07
  • Today's Open Interest 51,100
  • Open Int (30-Day) 50,866
  • Expected Range 530.26 to 565.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $4.37
  • Number of Estimates 6
  • High Estimate $4.46
  • Low Estimate $4.23
  • Prior Year $4.22
  • Growth Rate Est. (year over year) +3.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
465.00 +17.86%
on 07/23/26
555.32 -1.31%
on 08/21/26
+66.05 (+13.70%)
since 07/21/26
3-Month
420.01 +30.48%
on 06/03/26
555.32 -1.31%
on 08/21/26
+114.51 (+26.41%)
since 05/21/26
52-Week
374.17 +46.47%
on 09/24/25
555.32 -1.31%
on 08/21/26
+150.59 (+37.89%)
since 08/21/25

Most Recent Stories

More News
Are Wall Street Analysts Bullish on Vertex Stock?

Vertex Pharmaceuticals has raced ahead of the market, while analysts continue to give the stock a decidedly optimistic outlook.

XLV : 174.62 (+1.29%)
$SPX : 7,674.37 (+0.43%)
VRTX : 548.05 (+1.44%)
3 Cash-Producing Stocks on Our Watchlist

3 Cash-Producing Stocks on Our Watchlist

VRTX : 548.05 (+1.44%)
KRT : 48.05 (+1.01%)
YOU : 43.29 (+0.91%)
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals...

CRNX : 84.69 (unch)
VRTX : 548.05 (+1.44%)
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call

VRTX : 548.05 (+1.44%)
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations

Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations

VRTX : 548.05 (+1.44%)
Vertex: Q2 Earnings Snapshot

Vertex: Q2 Earnings Snapshot

VRTX : 548.05 (+1.44%)
Vertex Reports Second Quarter 2026 Financial Results

— Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 — — Raising full-year revenue guidance to $13.1 billion to $13.2 billion — ...

VRTX : 548.05 (+1.44%)
Jobs Numbers Set for Release Next Week

Monday U.S. Economic Lookahead S&P final U.S. manufacturing PMI (July) ISM manufacturing ...

SONY : 23.92 (+1.44%)
SNDK : 1,596.08 (-0.28%)
COP : 134.87 (-0.01%)
NVO : 46.74 (+1.30%)
CAT : 827.90 (+1.53%)
MRK : 152.55 (+2.39%)
VRTX : 548.05 (+1.44%)
AMD : 473.25 (+0.81%)
LLY : 1,255.40 (+0.88%)
PH : 1,001.74 (+0.16%)
PLTR : 179.94 (+3.44%)
MAR : 356.39 (-0.06%)
Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For

Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For

VRTX : 548.05 (+1.44%)
Vertex: The Cystic Fibrosis Franchise Meets Its First Real Comps Test

Barchart Research What to Expect from VRTX Earnings VRTX Generated July 31, 2026 Current Price $477.10 EPS Estimate $$4.30 Consensus Rating Moderate Buy Average Move 6.21% Vertex: The Cystic Fibrosis Franchise...

VRTX : 548.05 (+1.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 569.97
2nd Resistance Point 562.64
1st Resistance Point 555.35
Last Price 548.05
1st Support Level 540.73
2nd Support Level 533.40
3rd Support Level 526.11

See More

52-Week High 555.32
Last Price 548.05
Fibonacci 61.8% 486.12
Fibonacci 50% 464.74
Fibonacci 38.2% 443.37
52-Week Low 374.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.